Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.58 |
| ▸ | SRD5A2 | P31213 | 5/20 | 0.56 |
| ▸ | SRD5A1 | P18405 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TDP2 | O95551 | 1/20 | 0.51 |
| ▸ | TTR | P02766 | 2/20 | 0.47 |
| ▸ | PTPRC | P08575 | 2/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13131600 | 0.89 | ALDH1A1 (0.59) | PBRM1SRD5A2SRD5A1ALDH1A1TDP2 | |
| SCHEMBL552091 | 0.89 | ALDH1A1 (0.65) | PBRM1SRD5A2SRD5A1ALDH1A1TDP2 | |
| SCHEMBL29545918 | 0.89 | ALDH1A1 (0.65) | PBRM1SRD5A2SRD5A1ALDH1A1TDP2 | |
| SCHEMBL7050731 | 0.86 | TTR (0.58) | SRD5A2SRD5A1ALDH1A1TDP2TTR | |
| SCHEMBL29431442 | 0.85 | SRD5A2 (0.66) | PBRM1SRD5A2SRD5A1ALDH1A1TTR | |
| SCHEMBL1275273 | 0.85 | SRD5A2 (0.66) | PBRM1SRD5A2SRD5A1ALDH1A1TTR | |
| SCHEMBL18214525 | 0.84 | TTR (0.55) | SRD5A2SRD5A1ALDH1A1TDP2TTR | |
| SCHEMBL17327530 | 0.82 | TDP2 (0.62) | SRD5A2SRD5A1ALDH1A1TDP2TTR | |
| SCHEMBL17540270 | 0.80 | PBRM1 (0.53) | PBRM1SRD5A2SRD5A1TDP2 | |
| SCHEMBL10503011 | 0.80 | SRD5A2 (0.44) | PBRM1SRD5A2SRD5A1ALDH1A1TDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4486453-A1 | BENZAMIDE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2025-01-08 | — | — | EP | disclosed |
| CN-118843616-A | Benzamide compounds for the treatment of bacterial infections | 豪夫迈·罗氏有限公司 | 2024-10-25 | — | — | CN | disclosed |
| WO-2023166103-A1 | BENZAMIDE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-09-07 | — | — | WO | disclosed |
| CN-109563094-B | (hetero) aryl-substituted piperidinyl derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2022-03-18 | — | — | CN | disclosed |
| CN-114127638-A | Negative photosensitive resin composition, cured film, organic EL display, and method for producing cured film | 东丽株式会社 | 2022-03-01 | — | — | CN | disclosed |
| EP-2962992-B1 | FULLERENE DERIVATIVE, ORGANIC SOLAR CELL USING SAME, AND MANUFACTURING METHOD THEREOF | LG CHEMICAL LTD (KR) | 2021-07-07 | — | — | EP | disclosed |
| EP-2962992-B1 | FULLERENE DERIVATIVE, ORGANIC SOLAR CELL USING SAME, AND MANUFACTURING METHOD THEREOF | LG CHEMICAL LTD (KR) | 2021-07-07 | — | — | EP | disclosed |
| US-10711027-B2 | DNA polymerase beta inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-07-14 | — | — | US | disclosed |
| US-10654849-B2 | (Hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2020-05-19 | — | — | US | disclosed |
| EP-2704571-B1 | AMINO-PYRIDINE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK SHARP & DOHME (US) | 2020-04-22 | — | — | EP | disclosed |
| CN-1759095-A | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARM INC (US) | 2006-04-12 | — | — | CN | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005095387-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005087236-A1 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-09-22 | — | — | WO | disclosed |
| EP-1453789-A2 | N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | Elan Pharmaceuticals, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | PHARMACIA & UPJOHN COMPANY | 2004-09-02 | — | — | US | disclosed |
| US-6593335-B1 | Disease than can be ameliorated with a potassium channel opener in a host mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of the compound of claim 1; said disease is epilepsy, Raynaud's | ABBOTT LABORATORIES | 2003-07-15 | — | — | US | disclosed |
| WO-2003040096-A2 | N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| EP-1194429-A1 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2002-04-10 | — | — | EP | disclosed |
| WO-2000078768-A1 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711027-B2 | DNA polymerase beta inhibitors | POLB, POLH, POLN | PBRM1 748/4885SRD5A2 1235/4885SRD5A1 987/4885 |
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | BACE1, BACE2, PSEN1 | PBRM1 2182/4885SRD5A2 587/4885SRD5A1 349/4885 |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | PBRM1 988/4885SRD5A2 4393/4885SRD5A1 4146/4885 |
| US-10654849-B2 | (Hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | BAX, BCL2, CCNK | PBRM1 704/4885SRD5A2 3750/4885SRD5A1 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.